<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02082769</url>
  </required_header>
  <id_info>
    <org_study_id>SFDA2010L04287</org_study_id>
    <nct_id>NCT02082769</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Oral Febuxostat in Subjects With Gout</brief_title>
  <official_title>A Phase 3, Randomized, Multicenter, Allopurinol-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Qingdao Shengbang Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare febuxostat allopurinol in subjects with gout.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, multicenter, allopurinol-controlled and parallel-assigned study
      comparing 40 mg, 80 mg of febuxostat, and allopurinol 300 mg in subjects with gout. Subjects
      will receive treatment for 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Whose Last Three Serum Urate Levels Are &lt;6.0 Milligram Per Deciliter (mg/dL)</measure>
    <time_frame>Last 3 visits (any last 3 visits up to week 26)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Final Visit</measure>
    <time_frame>Final Visit (up to 26 weeks)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Absolute Change in the Serum Urate Level at the Final Visit Relative to Baseline</measure>
    <time_frame>Baseline and Final Visit (up to 26 weeks)</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">504</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Febuxostat 40 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat 40 mg, orally, once daily for up to 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat 80 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat 80 mg, orally, once daily for up to 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol 100mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allopurinol 100mg, orally, three times daily for up to 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <arm_group_label>Febuxostat 40 mg QD</arm_group_label>
    <arm_group_label>Febuxostat 80 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <arm_group_label>Allopurinol 100mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hyperuricemia (serum urate ≥8.0 mg/dL) and gout by Chinese Rheumatism Association
             Criteria;

          -  Renal function defined as a serum creatinine level of &lt; 2.0 mg/dL and creatinine
             clearance of &gt; 20 milliliters per minute (mL/min) by Cockcroft and Gault formula;

          -  No gout flare 2 weeks beforehand during 2-week screening period.

        Exclusion Criteria:

          -  Pregnancy or lactation;

          -  Concurrent therapy with urate lowering agents, azathioprine, 6-mercaptopurine,
             thiazide diuretics, or medications containing aspirin (&gt;325 mg) or other salicylates;

          -  Body Mass Index (BMI) &gt;50 kilogram per meter²(kg/m²);

          -  A history of active liver disease, or hepatic dysfunction;

          -  A history of bronchial asthma;

          -  A history of renal calculi or thyroid disease;

          -  Secondary gout Joint diseases induced by rheumatoid arthritis, psoriatic arthritis and
             bone tumor;

          -  Intolerance to allopurinol and Ibuprofen;

          -  Alcohol intake of ≥ 14 drinks/week;

          -  Clinically significant medical condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shenren Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Affiliated Hospital of Shantou University Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yangang Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Hospital of Qingdao University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiumei Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Shanxi Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Guangxi Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yongde Peng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianqin Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>LanZhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jinying Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>People's Hospital of Guangxi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haiwang Ji, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaanxi Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bin Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of Jilin University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ying Lu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Provincial Tongde Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peng Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Ruikang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yonghong Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Luoyang Orthopedic-Traumatological Hospital</affiliation>
  </overall_official>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2014</study_first_submitted>
  <study_first_submitted_qc>March 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2014</study_first_posted>
  <results_first_submitted>May 11, 2015</results_first_submitted>
  <results_first_submitted_qc>December 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2016</results_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gout</keyword>
  <keyword>Uric Acid</keyword>
  <keyword>Xanthine oxidase</keyword>
  <keyword>Febuxostat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Febuxostat 40 mg QD</title>
          <description>Febuxostat 40 mg, orally, once daily for up to 24 weeks
Febuxostat</description>
        </group>
        <group group_id="P2">
          <title>Febuxostat 80 mg QD</title>
          <description>Febuxostat 80 mg, orally, once daily for up to 24 weeks
Febuxostat</description>
        </group>
        <group group_id="P3">
          <title>Allopurinol 100mg QD</title>
          <description>Allopurinol 100mg, orally, three times daily for up to 24 weeks
Allopurinol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="141"/>
                <participants group_id="P3" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>full analysis set</population>
      <group_list>
        <group group_id="B1">
          <title>Febuxostat 40 mg QD</title>
          <description>Febuxostat 40 mg, orally, once daily for up to 24 weeks
Febuxostat</description>
        </group>
        <group group_id="B2">
          <title>Febuxostat 80 mg QD</title>
          <description>Febuxostat 80 mg, orally, once daily for up to 24 weeks
Febuxostat</description>
        </group>
        <group group_id="B3">
          <title>Allopurinol 100mg QD</title>
          <description>Allopurinol 100mg, orally, three times daily for up to 24 weeks
Allopurinol</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="160"/>
            <count group_id="B2" value="158"/>
            <count group_id="B3" value="159"/>
            <count group_id="B4" value="477"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="11.9"/>
                    <measurement group_id="B2" value="48.2" spread="12.0"/>
                    <measurement group_id="B3" value="46.5" spread="10.7"/>
                    <measurement group_id="B4" value="46.7" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.2" spread="2.7"/>
                    <measurement group_id="B2" value="25.1" spread="2.6"/>
                    <measurement group_id="B3" value="25.4" spread="3.3"/>
                    <measurement group_id="B4" value="25.2" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure (SBP)</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126.2" spread="10.0"/>
                    <measurement group_id="B2" value="126.4" spread="11.0"/>
                    <measurement group_id="B3" value="124.8" spread="10.1"/>
                    <measurement group_id="B4" value="126.4" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure (DBP)</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.1" spread="8.2"/>
                    <measurement group_id="B2" value="77.6" spread="8.1"/>
                    <measurement group_id="B3" value="78.7" spread="7.9"/>
                    <measurement group_id="B4" value="78.5" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline serum urate level units</title>
          <units>umol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="560.8" spread="73.3"/>
                    <measurement group_id="B2" value="565.1" spread="75.5"/>
                    <measurement group_id="B3" value="574.2" spread="77.8"/>
                    <measurement group_id="B4" value="566.7" spread="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Whose Last Three Serum Urate Levels Are &lt;6.0 Milligram Per Deciliter (mg/dL)</title>
        <time_frame>Last 3 visits (any last 3 visits up to week 26)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 24 weeks
Febuxostat</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 24 weeks
Febuxostat</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 100mg QD</title>
            <description>Allopurinol 100mg, orally, three times daily for up to 24 weeks
Allopurinol</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Last Three Serum Urate Levels Are &lt;6.0 Milligram Per Deciliter (mg/dL)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5"/>
                    <measurement group_id="O2" value="33.5"/>
                    <measurement group_id="O3" value="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Final Visit</title>
        <time_frame>Final Visit (up to 26 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 24 weeks
Febuxostat</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 24 weeks
Febuxostat</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 100mg QD</title>
            <description>Allopurinol 100mg, orally, three times daily for up to 24 weeks
Allopurinol</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Final Visit</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0"/>
                    <measurement group_id="O2" value="58.9"/>
                    <measurement group_id="O3" value="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Absolute Change in the Serum Urate Level at the Final Visit Relative to Baseline</title>
        <time_frame>Baseline and Final Visit (up to 26 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily for up to 24 weeks
Febuxostat</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 24 weeks
Febuxostat</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 100mg QD</title>
            <description>Allopurinol 100mg, orally, three times daily for up to 24 weeks
Allopurinol</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in the Serum Urate Level at the Final Visit Relative to Baseline</title>
          <units>umol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.2" spread="115.6"/>
                    <measurement group_id="O2" value="216.0" spread="137.2"/>
                    <measurement group_id="O3" value="170.4" spread="132.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Febuxostat 40 mg QD</title>
          <description>Febuxostat 40 mg, orally, once daily for up to 24 weeks
Febuxostat</description>
        </group>
        <group group_id="E2">
          <title>Febuxostat 80 mg QD</title>
          <description>Febuxostat 80 mg, orally, once daily for up to 24 weeks
Febuxostat</description>
        </group>
        <group group_id="E3">
          <title>Allopurinol 100mg QD</title>
          <description>Allopurinol 100mg, orally, three times daily for up to 24 weeks
Allopurinol</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hydronephrosis</sub_title>
                <description>The subject was diagnosed as hydronephrosis after 14-day period of febuxostat administration and thus hospitalized.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal electrocardiogram</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="168"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="168"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Others</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="168"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="168"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormalities</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="168"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="168"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal function test abnormalities</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="168"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Abnormal urine protein</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug allergy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="168"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Qiuhe Ji</name_or_title>
      <organization>Department of Endocrinology, Xijing Hospital, Fourth Military Medical University</organization>
      <phone>+86-29-84775213</phone>
      <email>qiuheji@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

